In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
Session

Event : ESC Congress 2019

Topic : Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure

  • Session type : Satellite Symposium
  • Date : 01 September 2019
  • Time : 15:00 - 16:00
  • Sponsored by Actelion Pharmaceuticals Ltd

5 presentations in this session

Introduction

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : M Humbert (Le Kremlin-Bicetre,FR)
  • Sponsored by Actelion Pharmaceuticals Ltd

Patient case: Part 1 - Realising the challenges and assessing the risk in pulmonary arterial hypertension

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : P de Groote (Lille,FR)
  • Sponsored by Actelion Pharmaceuticals Ltd

Patient case: Part 2 - Risk assessment-based management for optimal outcomes in pulmonary arterial hypertension

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : V McLaughlin (Ann Arbor,US)
  • Sponsored by Actelion Pharmaceuticals Ltd

Panel discussion - Pulmonary arterial hypertension

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : N Galie (Bologna,IT), M Humbert (Le Kremlin-Bicetre,FR)
  • Sponsored by Actelion Pharmaceuticals Ltd

Closing remarks

Event : ESC Congress 2019

  • Session : Pulmonary arterial hypertension – The importance of assessing risk in treatment and management to delay disease progression
  • Speaker : N Galie (Bologna,IT)
  • Sponsored by Actelion Pharmaceuticals Ltd

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are